Dr. Reddy's delays semaglutide supply due to ingredient issues, impacting shares but posing no safety risks.
More than half a dozen Indian drugmakers have launched
lower-cost copies of Novo Nordisk’s Ozempic and Wegovy, vying
for a share of the fast-growing global obesity treatment market
| Photo Credit:
quantic69
Dr. Reddy’s to delay semaglutide supplies due to quality issue, shares hit
Dr. Reddy’s to delay semaglutide supplies due to quality isssue, shares hit
Dr Reddy's flags quality issue in semaglutide batches, delays commercial supplies
Dr Reddy's shares slide 7% after delay in semaglutide supplies over quality concerns
Dr Reddy’s pauses weight loss drug on quality fears
Dr Reddy's shares crash 9% in 2 days; brokerages slash target prices after semaglutide supply disruption. What lies ahead?
Dr. Reddy’s halts semaglutide supplies on quality concerns, shares plunge, Torrent recalls product
Wegovy, Ozempic regain weight as Indian generics fall behind
Torrent Pharma recalls select batches of Semalix injection after Dr. Reddy's notice
Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to…
Dr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a…
